Giovanni Targher

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4466641/publications.pdf

Version: 2024-02-01

536 papers	44,608 citations	1980 101 h-index	2736 192 g-index
543 all docs	543 docs citations	543 times ranked	35746 citing authors

#	Article	IF	Citations
1	Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut, 2022, 71, 156-162.	6.1	162
2	A novel radiomics signature based on T2-weighted imaging accurately predicts hepatic inflammation in individuals with biopsy-proven nonalcoholic fatty liver disease: a derivation and independent validation study. Hepatobiliary Surgery and Nutrition, 2022, 11, 212-226.	0.7	4
3	Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies. Gut, 2022, 71, 778-788.	6.1	132
4	Non-alcoholic fatty liver disease in obese children and adolescents: a role for nutrition?. European Journal of Clinical Nutrition, 2022, 76, 28-39.	1.3	16
5	Sex influences the association between appendicular skeletal muscle mass to visceral fat area ratio and non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease. British Journal of Nutrition, 2022, 127, 1613-1620.	1.2	8
6	Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. Annals of the Rheumatic Diseases, 2022, 81, 68-73.	0.5	53
7	Interaction of SAMM50-rs738491, PARVB-rs5764455 and PNPLA3-rs738409 Increases Susceptibility to Nonalcoholic Steatohepatitis. Journal of Clinical and Translational Hepatology, 2022, 10, 219-229.	0.7	3
8	Nonâ€alcoholic fatty liver diseaseâ€related risk of cardiovascular disease and other cardiac complications. Diabetes, Obesity and Metabolism, 2022, 24, 28-43.	2.2	40
9	Non-alcoholic fatty liver disease is a risk factor for cardiovascular and cardiac diseases: further evidence that a holistic approach to treatment is needed. Gut, 2022, 71, 1695-1696.	6.1	11
10	A novel quantitative ultrasound technique for identifying nonâ€alcoholic steatohepatitis. Liver International, 2022, 42, 80-91.	1.9	6
11	PNPLA3 rs738409 C>G Variant Influences the Association Between Visceral Fat and Significant Fibrosis in Biopsy-proven Nonalcoholic Fatty Liver Disease. Journal of Clinical and Translational Hepatology, 2022, 10, 439-448.	0.7	1
12	All-cause mortality and cardiovascular events in patients with type 2 diabetes treated with alpha-glucosidase inhibitors: A meta-analysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 511-514.	1.1	5
13	The EASLâ€“Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet, The, 2022, 399, 61-116.	6.3	257
14	Metabolic Dysfunction-associated Fatty Liver Disease is Associated with Greater Impairment of Lung Function than Nonalcoholic Fatty Liver Disease. Journal of Clinical and Translational Hepatology, 2022, 10, 230-237.	0.7	15
15	Risk of HeartÂFailure in Patients With Nonalcoholic Fatty Liver Disease. Journal of the American College of Cardiology, 2022, 79, 180-191.	1.2	46
16	Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD. Metabolism: Clinical and Experimental, 2022, 128, 154958.	1.5	18
17	Ferroptosis and metabolic dysfunctionâ€associated fatty liver disease: Is there a link?. Liver International, 2022, 42, 1496-1502.	1.9	25
18	Association of metabolic dysfunction-associated fatty liver disease with kidney disease. Nature Reviews Nephrology, 2022, 18, 259-268.	4.1	72

#	Article	IF	Citations
19	Low cardiopulmonary fitness is associated with higher liver fat content and higher <scp>gammaâ€glutamyltransferase</scp> concentrations in the general population â€“ â€œThe Sedentaryâ€™s Liverâ€. Liver International, 2022, 42, 585-594.	1.9	3
20	Association between thyroid function and assessment of hepatic fat and iron contents by magnetic resonance imaging. Endocrine Connections, 2022, , .	0.8	2
21	Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. The Lancet Gastroenterology and Hepatology, 2022, 7, 367-378.	3.7	92
22	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 1-16.	1.1	15
23	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Digestive and Liver Disease, 2022, 54, 170-182.	0.4	12
24	Association between KLF6 rs3750861 polymorphism and plasma ceramide concentrations in post-menopausal women with type 2 diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 1283-1287.	1.1	1
25	J-shaped relationship between serum zinc levels and the severity of hepatic necro-inflammation in patients with MAFLD. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 1259-1265.	1.1	6
26	Risk of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis: an updated systematic review and meta-analysis of observational studies. Journal of Endocrinological Investigation, 2022, 45, 1277-1288.	1.8	26
27	Italian guidelines for the treatment of type 2 diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 770-814.	1.1	10
28	Association between higher serum uric acid levels and plasma N-terminal pro-B-type natriuretic peptide concentrations in patients with coronary artery disease and without overt heart failure. International Journal of Cardiology, 2022, , .	0.8	3
29	Associations of liver volume and other markers of hepatic steatosis with allâ€cause mortality in the general population. Liver International, 2022, 42, 575-584.	1.9	8
30	Association between hepatic iron overload assessed by magnetic resonance imaging and glucose intolerance states in the general population. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 1470-1476.	1.1	1
31	Effects of pioglitazone on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 529-536.	1.1	7
32	Effects of insulin on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases, 2022, , .	1.1	4
33	Glycemic control predicts the risk of hepatic fibrosis in biopsy-proven NAFLD: a possible mediating role for leukemia inhibitory factor?. , 2022, 1, 30-34.		2
34	Italian guidelines for the treatment of type 2 diabetes. Acta Diabetologica, 2022, 59, 579-622.	1.2	13
35	Potential Blood DNA Methylation Biomarker Genes for Diagnosis of Liver Fibrosis in Patients With Biopsy-Proven Non-alcoholic Fatty Liver Disease. Frontiers in Medicine, 2022, 9, 864570.	1.2	5
36	Global multi-stakeholder endorsement of the MAFLD definition. The Lancet Gastroenterology and Hepatology, 2022, 7, 388-390.	3.7	135

#	Article	IF	Citations
37	Tirzepatide adds hepatoprotection to its armoury. Lancet Diabetes and Endocrinology,the, 2022, 10, 374-375.	5.5	8
38	Hepatocellular cystathionine Î³ lyase/hydrogen sulfide attenuates nonalcoholic fatty liver disease by activating farnesoid X receptor. Hepatology, 2022, 76, 1794-1810.	3.6	24
39	Lifestyle Interventions for Non-Obese Patients Both with, and at Risk, of Non-Alcoholic Fatty Liver Disease. Diabetes and Metabolism Journal, 2022, 46, 391-401.	1.8	9
40	Elastographic parameters of liver steatosis and fibrosis predict independently the risk of incident chronic kidney disease and acute myocardial infarction in patients with type 2 diabetes mellitus. Journal of Diabetes and Its Complications, 2022, 36, 108226.	1.2	5
41	How should endocrinologists diagnose and treat non-alcoholic fatty liver disease?. Lancet Diabetes and Endocrinology,the, 2022, 10, 478-480.	5.5	0
42	Lower serum copper concentrations are associated with higher prevalence of nonalcoholic steatohepatitis: a matched caseâ€“control study. European Journal of Gastroenterology and Hepatology, 2022, 34, 838-843.	0.8	3
43	Editorial: higher levels of certain serum bile acids in nonâ€alcoholic fatty liver diseaseâ€”new insights from Guatemala. Alimentary Pharmacology and Therapeutics, 2022, 56, 357-360.	1.9	2
44	Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation. Nature Reviews Endocrinology, 2022, 18, 638-650.	4.3	18
45	Association between lower plasma adiponectin levels and higher liver stiffness in type 2 diabetic individuals with nonalcoholic fatty liver disease: an observational cross-sectional study. Hormones, 2022, 21, 477-486.	0.9	5
46	Low skeletal muscle mass is associated with more severe histological features of non-alcoholic fatty liver disease in male. Hepatology International, 2022, 16, 1085-1093.	1.9	6
47	Association between Higher Circulating Leucine-Rich Î±-2 Glycoprotein 1 Concentrations and Specific Plasma Ceramides in Postmenopausal Women with Type 2 Diabetes. Biomolecules, 2022, 12, 943.	1.8	1
48	FNDC5 polymorphism influences the association between sarcopenia and liver fibrosis in adults with biopsy-proven non-alcoholic fatty liver disease. British Journal of Nutrition, 2021, 126, 813-824.	1.2	11
49	Association between increased plasma ceramides and chronic kidney disease in patients with and without ischemic heart disease. Diabetes and Metabolism, 2021, 47, 101152.	1.4	28
50	Extrapulmonary complications of COVIDâ€19: A multisystem disease?. Journal of Medical Virology, 2021, 93, 323-335.	2.5	131
51	Association between lower plasma adiponectin levels and higher plasma thrombin generation parameters in men with type 2 diabetes: role of plasma triglycerides. Journal of Endocrinological Investigation, 2021, 44, 547-555.	1.8	5
52	NAFLD-related mortality: simple hepatic steatosis is not as â€˜benignâ€™ as thought. Gut, 2021, 70, 1212-1213.	6.1	22
53	Association between positivity of serum autoantibodies and liver disease severity in patients with biopsy-proven NAFLD. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 552-560.	1.1	7
54	Diffuse Idiopathic Skeletal Hyperostosis (DISH) in Type 2 Diabetes: A New Imaging Possibility and a New Biomarker. Calcified Tissue International, 2021, 108, 231-239.	1.5	12

#	Article	IF	Citations
55	MAFLD and risk of CKD. Metabolism: Clinical and Experimental, 2021, 115, 154433.	1.5	178
56	NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment. Diabetes and Metabolism, 2021, 47, 101215.	1.4	84
57	Effect of metformin on all-cause mortality and major adverse cardiovascular events: An updated meta-analysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 699-704.	1.1	26
58	Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut, 2021, 70, 962-969.	6.1	238
59	Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials. Metabolites, 2021, 11, 73.	1.3	145
60	Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease. Diagnostics, 2021, 11, 98.	1.3	59
61	Prevalence of hepatic steatosis in patients with type 2 diabetes and response to glucose-lowering treatments. A multicenter retrospective study in Italian specialist care. Journal of Endocrinological Investigation, 2021, 44, 1879-1889.	1.8	24
62	Nonalcoholic Fatty Liver Disease and Cardiovascular Disease. Clinical Liver Disease, 2021, 17, 19-22.	1.0	31
63	Nonalcoholic fatty liver disease â€“ a growing public health problem. Croatian Medical Journal, 2021, 62, 1-3.	0.2	5
64	Associations of Hydroxysteroid 17-beta Dehydrogenase 13 Variants with Liver Histology in Chinese Patients with Metabolic-associated Fatty Liver Disease. Journal of Clinical and Translational Hepatology, 2021, 000, 000-000.	0.7	5
65	Is COVID-19 lockdown associated with vitamin D deficiency?. European Journal of Public Health, 2021, 31, 278-279.	0.1	11
66	Association and Interaction Between Serum Interleukin-6 Levels and Metabolic Dysfunction-Associated Fatty Liver Disease in Patients With Severe Coronavirus Disease 2019. Frontiers in Endocrinology, 2021, 12, 604100.	1.5	25
67	Individualized Polygenic Risk Score Identifies NASH in the Eastern Asia Region: A Derivation and Validation Study. Clinical and Translational Gastroenterology, 2021, 12, e00321.	1.3	6
68	TA allele of rs2070673 in the CYP2E1 gene is associated with lobular inflammation and nonalcoholic steatohepatitis in patients with biopsyâ€proven nonalcoholic fatty liver disease. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2925-2934.	1.4	6
69	Machine learning algorithm outperforms fibrosis markers in predicting significant fibrosis in biopsyâ€confirmed NAFLD. Journal of Hepato-Biliary-Pancreatic Sciences, 2021, 28, 593-603.	1.4	19
70	Association between MBOAT7 rs641738 polymorphism and non-alcoholic fatty liver in overweight or obese children. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 1548-1555.	1.1	14
71	The complex link between NAFLD and type 2 diabetes mellitus â€” mechanisms and treatments. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 599-612.	8.2	346
72	The HSD17B13 rs72613567 variant is associated with lower levels of albuminuria in patients with biopsy-proven nonalcoholic fatty liver disease. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 1822-1831.	1.1	8

#	Article	IF	Citations
73	Significant liver fibrosis, as assessed by fibroscan, is independently associated with chronic vascular complications of type 2 diabetes: A multicenter study. Diabetes Research and Clinical Practice, 2021, 177, 108884.	1.1	15
74	Plasma Bile Acid Profile in Patients with and without Type 2 Diabetes. Metabolites, 2021, 11, 453.	1.3	28
75	Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. The Lancet Gastroenterology and Hepatology, 2021, 6, 578-588.	3.7	206
76	Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease. Trends in Endocrinology and Metabolism, 2021, 32, 500-514.	3.1	101
77	Beneficial effects of glucagon-like peptide 1 receptor agonists on glucose control, cardiovascular risk profile, and non-alcoholic fatty liver disease. An expert opinion of the Italian diabetes society. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 3257-3270.	1.1	7
78	Improvement of glycemic control in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 2539-2546.	1.1	17
79	Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic steatohepatitis: new insights from subcutaneous semaglutide. Hepatobiliary Surgery and Nutrition, 2021, 10, 518-521.	0.7	5
80	Association between non-alcoholic fatty liver disease and impaired cardiac sympathetic/parasympathetic balance in subjects with and without type 2 diabetesâ€"The Cooperative Health Research in South Tyrol (CHRIS)-NAFLD sub-study. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 3464-3473.	1.1	14
81	Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases. The Lancet Gastroenterology and Hepatology, 2021, 6, 743-753.	3.7	60
82	Coffee, Atrial Fibrillation, and Circulating Ceramides in Patients with Chronic Heart Failure. Journal of Agricultural and Food Chemistry, 2021, 69, 11236-11245.	2.4	5
83	Type 2 Diabetes and Dietary Carbohydrate Intake of Adolescents and Young Adults: What Is the Impact of Different Choices?. Nutrients, 2021, 13, 3344.	1.7	11
84	Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. The Lancet Gastroenterology and Hepatology, 2021, 6, 903-913.	3.7	227
85	Changes in markers of hepatic steatosis and fibrosis in patients with type 2 diabetes during treatment with glucagon-like peptide-1 receptor agonists. A multicenter retrospective longitudinal study. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 3474-3483.	1.1	7
86	acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study. EClinicalMedicine, 2021, 41, 101145.	3.2	14
87	Optimal thresholds for ultrasound attenuation parameter in the evaluation of hepatic steatosis severity: evidence from a cohort of patients with biopsy-proven fatty liver disease. European Journal of Gastroenterology and Hepatology, 2021, 33, 430-435.	0.8	12
88	Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. Metabolites, 2021, 11, 22.	1.3	72
89	Growth differentiation factor-15 and the association between type 2 diabetes and liver fibrosis in NAFLD. Nutrition and Diabetes, 2021, 11, 32.	1.5	13
90	Prognostic Role of Pericardial Fat on the Incidence of HeartÂFailure. Journal of the American College of Cardiology, 2021, 78, e111.	1.2	0

#	Article	IF	Citations
91	Long-term outcomes in patients with non-alcoholic fatty liver disease: further evidence that a multidisciplinary and patient-centred approach to treatment is needed. Hepatobiliary Surgery and Nutrition, 2021, 11, 0-0.	0.7	1
92	Non-Alcoholic Fatty Liver Disease Is Associated With Reduced Glomerular Filtration Rate in Patients With Chronic Plaque Psoriasis. Journal of Cutaneous Medicine and Surgery, 2021, , 120347542110669.	0.6	1
93	Association between specific plasma ceramides and high-sensitivity C-reactive protein levels in postmenopausal women with type 2 diabetes. Diabetes and Metabolism, 2020, 46, 326-330.	1.4	9
94	Associations between specific plasma ceramides and severity of coronary-artery stenosis assessed by coronary angiography. Diabetes and Metabolism, 2020, 46, 150-157.	1.4	29
95	Effect of PNPLA3 polymorphism on diagnostic performance of various noninvasive markers for diagnosing and staging nonalcoholic fatty liver disease. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1057-1064.	1.4	27
96	PNPLA3 rs738409 is associated with renal glomerular and tubular injury in NAFLD patients with persistently normal ALT levels. Liver International, 2020, 40, 107-119.	1.9	67
97	Liver fibrosis by FibroScan^{Â®} independently of established cardiovascular risk parameters associates with macrovascular and microvascular complications in patients with type 2 diabetes. Liver International, 2020, 40, 347-354.	1.9	59
98	Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials. Diabetes and Metabolism, 2020, 46, 427-441.	1.4	81
99	Prospective evaluation of non-alcoholic fatty liver disease by elastographic methods of liver steatosis and fibrosis; controlled attenuation parameter and liver stiffness measurements. Journal of Diabetes and Its Complications, 2020, 34, 107512.	1.2	11
100	Whatâ€™s new in NAFLD pathogenesis, biomarkers and treatment?. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 70-71.	8.2	40
101	High-Dose Vitamin D Supplementation and Bone Health. JAMA - Journal of the American Medical Association, 2020, 323, 92.	3.8	3
102	Cardiovascular Risk in NAFLD: An Intimate Relationship?. Digestive Diseases and Sciences, 2020, 65, 1593-1595.	1.1	4
103	Treatment algorithm in patients with type 2 diabetes and atherosclerotic cardiovascular disease or high/very high cardiovascular risk. European Heart Journal, 2020, 41, 331-331.	1.0	5
104	Higher liver stiffness scores are associated with early kidney dysfunction in patients with histologically proven non-cirrhotic NAFLD. Diabetes and Metabolism, 2020, 46, 288-295.	1.4	24
105	Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes. Diabetes and Metabolism, 2020, 46, 296-303.	1.4	47
106	P1737 Echocardiographic estimation of pulmonary artery pressure in young non-complicated patients with type 1 diabetes: results from a single-center observational study. European Heart Journal Cardiovascular Imaging, 2020, 21, .	0.5	0
107	NAFLD fibrosis score (NFS) can be used in outpatient services to identify chronic vascular complications besides advanced liver fibrosis in type 2 diabetes. Journal of Diabetes and Its Complications, 2020, 34, 107684.	1.2	11
108	Management of type 2 diabetes for prevention of cardiovascular disease. An expert opinion of the Italian Diabetes Society. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1926-1936.	1.1	7

#	Article	IF	Citations
109	Concordance between MAFLD and NAFLD diagnostic criteria in â€˜realâ€worldâ€™ data. Liver International, 2020, 40, 2879-2880.	1.9	27
110	Whatâ€™s Past Is Prologue: History of Nonalcoholic Fatty Liver Disease. Metabolites, 2020, 10, 397.	1.3	6
111	Abnormal liver enzymes in children and infants with <scp>COVID</scp>â€19: A narrative review of caseâ€series studies. Pediatric Obesity, 2020, 15, e12723.	1.4	18
112	Editorial: a diabetologist's perspective on the diagnosis and monitoring of NAFLD. Alimentary Pharmacology and Therapeutics, 2020, 52, 710-711.	1.9	3
113	Nonalcoholic Fatty Liver Disease and Estimated Insulin Resistance in Obese Youth: A Mendelian Randomization Analysis. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4046-e4054.	1.8	27
114	ACE2: A Linkage for the Interplay Between COVID-19 and Decompensated Cirrhosis. American Journal of Gastroenterology, 2020, 115, 1544-1544.	0.2	14
115	Human and molecular genetics shed lights on fatty liver disease and diabetes conundrum. Endocrinology, Diabetes and Metabolism, 2020, 3, e00179.	1.0	10
116	Pre-existing type 2 diabetes is associated with increased all-cause death independently of echocardiographic predictors of poor prognosis only in ischemic heart disease. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 2036-2040.	1.1	1
117	Is it time for non-alcoholic fatty liver disease screening in patients with type 2 diabetes mellitus?. Hepatobiliary Surgery and Nutrition, 2020, 9, 239-241.	0.7	9
118	Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. Gut, 2020, 69, 1545-1547.	6.1	166
119	Patients with diabetes are at higher risk for severe illness from COVID-19. Diabetes and Metabolism, 2020, 46, 335-337.	1.4	124
120	Obesity Is a Risk Factor for Greater COVID-19 Severity. Diabetes Care, 2020, 43, e72-e74.	4.3	323
121	Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: A meta-analysis of observational studies. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1236-1248.	1.1	196
122	Effect of insulin secretagogues on major cardiovascular events and all-cause mortality: A meta-analysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1601-1608.	1.1	18
123	Detrimental effects of metabolic dysfunction-associated fatty liver disease and increased neutrophil-to-lymphocyte ratio on severity of COVID-19. Diabetes and Metabolism, 2020, 46, 505-507.	1.4	34
124	PNPLA3I148M gene variant and chronic kidney disease in type 2 diabetic patients with NAFLD: Clinical and experimental findings. Liver International, 2020, 40, 1130-1141.	1.9	33
125	Global epidemiology of lean nonâ€alcoholic fatty liver disease: A systematic review and metaâ€analysis. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 2041-2050.	1.4	67
126	Nonalcoholic Fatty Liver Disease and Implications for Older Adults with Diabetes. Clinics in Geriatric Medicine, 2020, 36, 527-547.	1.0	5

#	Article	IF	Citations
127	Lower levels of plasma NT-proBNP are associated with higher prevalence of NASH in patients with biopsy-proven NAFLD. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1820-1825.	1.1	9
128	Relation between plasma ceramides and cardiovascular death in chronic heart failure: A subset analysis of the GISSIâ€HF trial. ESC Heart Failure, 2020, 7, 3288-3297.	1.4	12
129	PNPLA3 polymorphism influences the association between high-normal TSH level and NASH in euthyroid adults with biopsy-proven NAFLD. Diabetes and Metabolism, 2020, 46, 496-503.	1.4	5
130	Further advices on measuring lipoprotein(a) for reducing the residual cardiovascular risk on statin therapy. Clinical Chemistry and Laboratory Medicine, 2020, 58, e144-e147.	1.4	2
131	Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology, 2020, 158, 1597-1610.e7.	0.6	123
132	Is Nonalcoholic Fatty Liver Disease Not a Risk Factor for Cardiovascular Disease: Not Yet Time for a Change of Heart. Hepatology, 2020, 71, 1867-1869.	3.6	12
133	Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2020, 111, 154170.	1.5	278
134	Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity. Annals of Hepatology, 2020, 19, 359-366.	0.6	81
135	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. Journal of Hepatology, 2020, 73, 202-209.	1.8	2,171
136	Development and validation of a novel nonâ€invasive test for diagnosing fibrotic nonâ€alcoholic steatohepatitis in patients with biopsyâ€proven nonâ€alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1804-1812.	1.4	15
137	Combined and sequential non-invasive approach to diagnosing non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease and persistently normal alanine aminotransferase levels. BMJ Open Diabetes Research and Care, 2020, 8, e001174.	1.2	21
138	NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut, 2020, 69, 1691-1705.	6.1	369
139	NAFLD as a driver of chronic kidney disease. Journal of Hepatology, 2020, 72, 785-801.	1.8	249
140	COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies. Journal of Clinical and Translational Hepatology, 2020, 8, 1-7.	0.7	329
141	Diabetes and NAFLD. Endocrinology, 2020, , 495-521.	0.1	0
142	GLP-1 receptor agonists for NAFLD treatment in patients with and without type 2 diabetes: an updated meta-analysis. Exploration of Medicine, 2020, 1, 108-123.	1.5	3
143	Echocardiographic parameters according to insulin dose in young patients affected by type 1 diabetes. PLoS ONE, 2020, 15, e0244483.	1.1	0
144	NAFLD, Diabetes, and Other Endocrine Diseases: Clinical Implications. , 2020, , 147-168.		0

#	Article	IF	Citations
145	Plasma Nâ€terminal propeptide of type III procollagen accurately predicts liver fibrosis severity in children with nonâ€alcoholic fatty liver disease. Liver International, 2019, 39, 2317-2329.	1.9	24
146	Increased aortic stiffness in adults with chronic indeterminate Chagas disease. PLoS ONE, 2019, 14, e0220689.	1.1	2
147	Prevalence of prediabetes and diabetes in children and adolescents with biopsy-proven non-alcoholic fatty liver disease. Journal of Hepatology, 2019, 71, 802-810.	1.8	39
148	Contribution of a genetic risk score to clinical prediction of hepatic steatosis in obese children and adolescents. Digestive and Liver Disease, 2019, 51, 1586-1592.	0.4	34
149	THU-323-Impact of genetic polymorphisms associated with NAFLD on hepatic and vascular complications in diabetes. Journal of Hepatology, 2019, 70, e302.	1.8	0
150	Association Between Nonalcoholic Fatty Liver Disease and Reduced Bone Mineral Density in Children: A Metaâ€Analysis. Hepatology, 2019, 70, 812-823.	3.6	30
151	Association between nonâ€alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: An updated metaâ€analysis. Liver International, 2019, 39, 758-769.	1.9	75
152	NAFLD in Some Common Endocrine Diseases: Prevalence, Pathophysiology, and Principles of Diagnosis and Management. International Journal of Molecular Sciences, 2019, 20, 2841.	1.8	79
153	Association between non-alcoholic fatty liver disease and decreased lung function in adults: A systematic review and meta-analysis. Diabetes and Metabolism, 2019, 45, 536-544.	1.4	25
154	Risk of atrial fibrillation in patients with nonalcoholic steatohepatitis. Liver International, 2019, 39, 818-820.	1.9	0
155	Association between Helicobacter pylori infection and risk of nonalcoholic fatty liver disease: An updated meta-analysis. Metabolism: Clinical and Experimental, 2019, 96, 56-65.	1.5	38
156	Impact of genetic polymorphisms associated with NAFLD on hepatic and vascular complications in diabetes. Digestive and Liver Disease, 2019, 51, e28-e29.	0.4	0
157	Relationship Between PNPLA3 rs738409 Polymorphism and Decreased Kidney Function in Children With NAFLD. Hepatology, 2019, 70, 142-153.	3.6	44
158	Increased aortic stiffness index in patients with type 1 diabetes without cardiovascular disease compared to controls. Journal of Endocrinological Investigation, 2019, 42, 1109-1115.	1.8	5
159	Letter: nonâ€alcoholic fatty liver disease is associated with a history of osteoporotic fractures but not with low bone mineral densityâ€"authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2019, 49, 961-962.	1.9	0
160	Influence of hypertriglyceridemia, hyperbilirubinemia and hemolysis on thrombin generation in human plasma. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1784-1789.	1.4	12
161	Editorial: importance of an elevated mean platelet volume for prediction of major adverse cardiovascular events in nonâ€alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics, 2019, 49, 1092-1093.	1.9	2
162	Pathogenesis of hypothyroidism-induced NAFLD: Evidence for a distinct disease entity?. Digestive and Liver Disease, 2019, 51, 462-470.	0.4	44

#	Article	IF	Citations
163	Association between PNPLA3rs738409 polymorphism decreased kidney function in postmenopausal type 2 diabetic women with or without non-alcoholic fatty liver disease. Diabetes and Metabolism, 2019, 45, 480-487.	1.4	36
164	Systematic review with metaâ€analysis: nonâ€alcoholic fatty liver disease is associated with a history of osteoporotic fractures but not with low bone mineral density. Alimentary Pharmacology and Therapeutics, 2019, 49, 375-388.	1.9	45
165	Does high LDL-cholesterol cause cardiovascular disease?. Expert Review of Clinical Pharmacology, 2019, 12, 91-91.	1.3	2
166	Association between non-alcoholic fatty liver disease and bone turnover biomarkers in post-menopausal women with type 2 diabetes. Diabetes and Metabolism, 2019, 45, 347-355.	1.4	47
167	Are we overrating the extra-skeletal benefits of oral vitamin D supplementation?. Annals of Translational Medicine, 2019, 7, 499-499.	0.7	2
168	Diabetes and NAFLD. Endocrinology, 2019, , 1-27.	0.1	0
169	Increased red blood cell distribution width and plateletâ€toâ€lymphocyte ratio for predicting allâ€cause mortality in patients with type 2 diabetes and advanced heart failure: a causal association or epiphenomenon?. Kardiologia Polska, 2019, 77, 587-588.	0.3	0
170	Estimating the real burden of cardiovascular mortality in diabetes. European Review for Medical and Pharmacological Sciences, 2019, 23, 6700-6706.	0.5	3
171	Long-Acting GLP-1 Receptor Agonist Exenatide Influence on the Autonomic Cardiac Sympatho-Vagal Balance. Journal of the Endocrine Society, 2018, 2, 53-62.	0.1	8
172	Prognostic impact of elevated serum uric acid levels on long-term outcomes in patients with chronic heart failure: A post-hoc analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 205-215.	1.5	30
173	From a fatty liver to a sugary blood. Digestive and Liver Disease, 2018, 50, 378-380.	0.4	4
174	Mortality from infectious diseases in diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 444-450.	1.1	43
175	Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis. Diabetes Care, 2018, 41, 372-382.	4.3	407
176	Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. Nature Reviews Endocrinology, 2018, 14, 99-114.	4.3	284
177	Non-alcoholic fatty liver disease and increased risk of all-cause mortality in elderly patients admitted for acute heart failure. International Journal of Cardiology, 2018, 265, 162-168.	0.8	41
178	Liver fat content, non-alcoholic fatty liver disease, and risk of ischaemic heart disease. European Heart Journal, 2018, 39, 3398-3398.	1.0	3
179	Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 425-439.	8.2	207
180	Diabetes and NAFLD. Endocrinology, 2018, , 1-27.	0.1	0

#	Article	IF	Citations
181	Hyperuricemia is associated with an increased prevalence of paroxysmal atrial fibrillation in patients with type 2 diabetes referred for clinically indicated 24-h Holter monitoring. Journal of Endocrinological Investigation, 2018, 41, 223-231.	1.8	17
182	Psoriasis and the metabolic syndrome. Clinics in Dermatology, 2018, 36, 21-28.	0.8	211
183	Clinical relevance of liver histopathology and different histological classifications of NASH in adults. Expert Review of Gastroenterology and Hepatology, 2018, 12, 351-367.	1.4	47
184	Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?. Journal of Hepatology, 2018, 68, 335-352.	1.8	495
185	Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis. Metabolism: Clinical and Experimental, 2018, 79, 64-76.	1.5	261
186	Association of Plasma Ceramides With Myocardial Perfusion in Patients With Coronary Artery Disease Undergoing Stress Myocardial Perfusion Scintigraphy. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 2854-2861.	1.1	29
187	The E/eâ€™ ratio difference between subjects with type 2 diabetes and controls. A meta-analysis of clinical studies. PLoS ONE, 2018, 13, e0209794.	1.1	10
188	Association between decreasing estimated glomerular filtration rate and risk of cardiac conduction defects in patients with type 2 diabetes. Diabetes and Metabolism, 2018, 44, 473-481.	1.4	2
189	Association between plasma ceramides and inducible myocardial ischemia in patients with established or suspected coronary artery disease undergoing myocardial perfusion scintigraphy. Metabolism: Clinical and Experimental, 2018, 85, 305-312.	1.5	15
190	Association between nonalcoholic fatty liver disease and colorectal tumours in asymptomatic adults undergoing screening colonoscopy: a systematic review and meta-analysis. Metabolism: Clinical and Experimental, 2018, 87, 1-12.	1.5	80
191	Stereotactic body radiotherapy for lung oligometastases impacts on systemic treatment-free survival: a cohort study. Medical Oncology, 2018, 35, 121.	1.2	28
192	Left ventricular chamber dilation and filling pressure may help to categorise patients with type 2 diabetes. BMJ Open Diabetes Research and Care, 2018, 6, e000529.	1.2	4
193	Tests for diagnosing and monitoring non-alcoholic fatty liver disease in adults. BMJ: British Medical Journal, 2018, 362, k2734.	2.4	81
194	Ad Libitum Mediterranean or Lowâ€Fat Diets as Treatments for Nonalcoholic Fatty Liver Disease?. Hepatology, 2018, 68, 1668-1671.	3.6	6
195	Association Between Primary Hypothyroidism and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Thyroid, 2018, 28, 1270-1284.	2.4	87
196	Diabetes and NAFLD. Endocrinology, 2018, , 495-521.	0.1	0
197	Early impairment in left ventricular longitudinal systolic function is associated with an increased risk of incident atrial fibrillation in patients with type 2 diabetes. Journal of Diabetes and Its Complications, 2017, 31, 413-418.	1.2	24
198	Psychological distress, self-efficacy and glycemic control in type 2 diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 300-306.	1.1	51

#	Article	IF	Citations
199	AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. Digestive and Liver Disease, 2017, 49, 471-483.	0.4	254
200	â€œ Not all forms of NAFLD were created equal â€• Do metabolic syndrome-related NAFLD and PNPLA3 -related NAFLD exert a variable impact on the risk of early carotid atherosclerosis?. Atherosclerosis, 2017, 257, 253-255.	0.4	26
201	Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease. Nature Reviews Nephrology, 2017, 13, 297-310.	4.1	219
202	Nonalcoholic fatty liver disease is associated with an increased prevalence of distal symmetric polyneuropathy in adult patients with type 1 diabetes. Journal of Diabetes and Its Complications, 2017, 31, 1021-1026.	1.2	47
203	Association Between Diabetes and 1-Year Adverse Clinical Outcomes in a Multinational Cohort of Ambulatory Patients With Chronic Heart Failure: Results From the ESC-HFA Heart Failure Long-Term Registry. Diabetes Care, 2017, 40, 671-678.	4.3	103
204	Association between subclinical left ventricular systolic dysfunction and glycemic control in asymptomatic type 2 diabetic patients with preserved left ventricular function. Journal of Diabetes and Its Complications, 2017, 31, 1035-1040.	1.2	11
205	Non-alcoholic fatty liver disease as driving force in coronary heart disease?. Gut, 2017, 66, 213-214.	6.1	10
206	Effect of aspirin on renal disease progression in patients with type 2 diabetes: A multicenter, double-blind, placebo-controlled, randomized trial. The renaL disEase progression by aspirin in diabetic pAtients (LEDA) trial. Rationale and study design. American Heart Journal, 2017, 189, 120-127.	1.2	10
207	Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases. Metabolism: Clinical and Experimental, 2017, 72, 57-65.	1.5	110
208	Low-grade endotoxemia, gut permeability and platelet activation in patients with impaired fasting glucose. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 890-895.	1.1	26
209	Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut, 2017, 66, 1138-1153.	6.1	807
210	Relation of elevated serum uric acid levels to first-degree heart block and other cardiac conduction defects in hospitalized patients with type 2 diabetes. Journal of Diabetes and Its Complications, 2017, 31, 1691-1697.	1.2	10
211	A fatty liver leads to decreased kidney function?. Journal of Hepatology, 2017, 67, 1137-1139.	1.8	10
212	Prognostic Impact of Diabetes on Long-term Survival Outcomes in Patients With Heart Failure: A Meta-analysis. Diabetes Care, 2017, 40, 1597-1605.	4.3	82
213	Prognostic Impact of Diabetes and Prediabetes on Survival Outcomes in Patients With Chronic Heart Failure: A Postâ€Hoc Analysis of the GISSIâ€HF (Gruppo Italiano per lo Studio della Sopravvivenza nella) Tj ETQq1 1 0.784314 rgBT /O		
214	Inâ€hospital and 1â€year mortality associated with diabetes in patients with acute heart failure: results from the <scp>ESCâ€HFA</scp> Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2017, 19, 54-65.	2.9	150
215	Plasma Leptin in Patients at Intermediate to High Cardiovascular Risk With and Without Type 2 Diabetes Mellitus. Journal of Clinical Laboratory Analysis, 2017, 31, e22031.	0.9	5
216	Mitral Regurgitation and Increased Risk of All-Cause and Cardiovascular Mortality in Patients with Type 2 Diabetes. American Journal of Medicine, 2017, 130, 70-76.e1.	0.6	18

#	Article	IF	Citations
217	Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease. Annals of Translational Medicine, 2017, 5, 270-270.	0.7	109
218	NAFLD: Is There Anything New under the Sun?. International Journal of Molecular Sciences, 2017, 18, 1955.	1.8	7
219	Nonalcoholic fatty liver disease and increased risk of 1-year all-cause and cardiac hospital readmissions in elderly patients admitted for acute heart failure. PLoS ONE, 2017, 12, e0173398.	1.1	38
220	Nonalcoholic fatty liver disease is associated with an increased risk of heart block in hospitalized patients with type 2 diabetes mellitus. PLoS ONE, 2017, 12, e0185459.	1.1	42
221	Relationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis?. International Journal of Molecular Sciences, 2016, 17, 217.	1.8	73
222	Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infectionâ€"Liver: The â€œMusketeerâ€•in the Spotlight. International Journal of Molecular Sciences, 2016, 17, 355.	1.8	36
223	Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. World Journal of Gastroenterology, 2016, 22, 9674.	1.4	93
224	Echocardiographically Derived Pulse Wave Velocity and Diastolic Dysfunction Are Associated with an Increased Incidence of Atrial Fibrillation in Patients with Systolic Heart Failure. Echocardiography, 2016, 33, 1024-1031.	0.3	10
225	Nonalcoholic fatty liver disease, cardiovascular outcomes, and mortality in patients undergoing a coronary angiogram. Hepatology, 2016, 64, 684-685.	3.6	4
226	Global epidemiology of nonalcoholic fatty liver disease: Metaâ€•analytic assessment of prevalence, incidence, and outcomes. Hepatology, 2016, 64, 1388-1389.	3.6	104
227	Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and metaâ€•analysis. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 936-944.	1.4	537
228	Nonalcoholic Fatty Liver Disease Is Associated With Ventricular Arrhythmias in Patients With Type 2 Diabetes Referred for Clinically Indicated 24-Hour Holter Monitoring. Diabetes Care, 2016, 39, 1416-1423.	4.3	95
229	Factors associated with significant liver steatosis and fibrosis as assessed by transient elastography in patients with one or more components of the metabolic syndrome. Journal of Diabetes and Its Complications, 2016, 30, 1347-1353.	1.2	43
230	Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. Journal of Hepatology, 2016, 65, 589-600.	1.8	965
231	EASLâ€"EASDâ€"EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: is universal screening appropriate?. Diabetologia, 2016, 59, 1141-1144.	2.9	78
232	Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon?. Diabetes and Metabolism, 2016, 42, 142-156.	1.4	78
233	Severe hypoglycemia in patients with known diabetes requiring emergency department care: A report from an Italian multicenter study. Journal of Clinical and Translational Endocrinology, 2016, 5, 46-52.	1.0	8
234	Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes?. Liver International, 2016, 36, 1563-1579.	1.9	126

#	Article	IF	Citations
235	Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular disease in adult patients with type 1 diabetes. International Journal of Cardiology, 2016, 225, 387-391.	0.8	56
236	The aspartate aminotransferase-to-alanine aminotransferase ratio predicts all-cause and cardiovascular mortality in patients with type 2 diabetes. Medicine (United States), 2016, 95, e4821.	0.4	47
237	Evidence of left atrial remodeling and left ventricular diastolic dysfunction in type 2 diabetes mellitus with preserved systolic function. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 1026-1032.	1.1	16
238	Metabolically healthy obesity and NAFLD. Nature Reviews Gastroenterology and Hepatology, 2016, 13, 442-444.	8.2	55
239	Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis?. Endocrine, 2016, 51, 211-221.	1.1	69
240	Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease. Digestive Diseases and Sciences, 2016, 61, 1246-1267.	1.1	99
241	Nonalcoholic Fatty Liver Disease Is Associated With Higher 1-year All-Cause Rehospitalization Rates in Patients Admitted for Acute Heart Failure. Medicine (United States), 2016, 95, e2760.	0.4	17
242	A â€œsystems medicineâ€•approach to the study of non-alcoholic fatty liver disease. Digestive and Liver Disease, 2016, 48, 333-342.	0.4	56
243	Association between hepatic steatosis and serum liver enzyme levels with atrial fibrillation in the general population. Atherosclerosis, 2016, 245, 123-131.	0.4	42
244	Prognostic impact of in-hospital hyperglycemia in hospitalized patients with acute heart failure: Results of the IN-HF (Italian Network on Heart Failure) Outcome registry. International Journal of Cardiology, 2016, 203, 587-593.	0.8	33
245	Time to Replace Assessment of Liver Histology With MR-Based Imaging Tests to Assess Efficacy of Interventions for Nonalcoholic Fatty Liver Disease. Gastroenterology, 2016, 150, 7-10.	0.6	36
246	Non-alcoholic fatty liver disease and risk of cardiovascular disease. Metabolism: Clinical and Experimental, 2016, 65, 1136-1150.	1.5	190
247	Hyperuricemia is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes. Journal of Endocrinological Investigation, 2016, 39, 159-167.	1.8	28
248	Black esophagus syndrome associated with diabetic ketoacidosis. World Journal of Clinical Cases, 2016, 4, 56.	0.3	21
249	Gallstone Disease and Increased Risk of Ischemic Heart Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 2073-2075.	1.1	10
250	Nonalcoholic Fatty Liver Disease Is Independently Associated with Early Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes. PLoS ONE, 2015, 10, e0135329.	1.1	81
251	Nonalcoholic fatty liver disease and decreased bone mineral density: is there a link?. Journal of Endocrinological Investigation, 2015, 38, 817-825.	1.8	70
252	Heart valve calcification in patients with type 2 diabetes and nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2015, 64, 879-887.	1.5	82

#	Article	IF	Citations
253	Lower levels of 25-hydroxyvitamin D₃are associated with a higher prevalence of microvascular complications in patients with type 2 diabetes. BMJ Open Diabetes Research and Care, 2015, 3, e000058.	1.2	45
254	The mean platelet volume is significantly associated with higher glycated hemoglobin in a large population of unselected outpatients. Primary Care Diabetes, 2015, 9, 226-230.	0.9	26
255	Prevalence of diabetes across different immigrant groups in North-eastern Italy. Nutrition, Metabolism and Cardiovascular Diseases, 2015, 25, 924-930.	1.1	15
256	Prevalence of neuropathy in type 2 diabetic patients and its association with other diabetes complications: The Verona Diabetic Foot Screening Program. Journal of Diabetes and Its Complications, 2015, 29, 1066-1070.	1.2	69
257	Understanding the association between developing a fatty liver and subsequent cardio-metabolic complications. Expert Review of Gastroenterology and Hepatology, 2015, 9, 1243-1245.	1.4	23
258	Relationship between increased left atrial volume and microvascular complications in patients with type 2 diabetes. Journal of Diabetes and Its Complications, 2015, 29, 822-828.	1.2	12
259	Prevalence of Cardiovascular Autonomic Neuropathy in a Cohort of Patients With Newly Diagnosed Type 2 Diabetes: The Verona Newly Diagnosed Type 2 Diabetes Study (VNDS). Diabetes Care, 2015, 38, 1487-1493.	4.3	55
260	NAFLD: A multisystem disease. Journal of Hepatology, 2015, 62, S47-S64.	1.8	2,037
261	Circulating Markers of Liver Function and Cardiovascular Disease Risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 2290-2296.	1.1	54
262	A Perspective on Metabolic Syndrome and Nonalcoholic Fatty Liver Disease. Metabolic Syndrome and Related Disorders, 2015, 13, 235-238.	0.5	27
263	Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Digestive and Liver Disease, 2015, 47, 997-1006.	0.4	368
264	Nonalcoholic fatty liver disease is independently associated with early left ventricular diastolic dysfunction in patients with type 2 diabetes. Digestive and Liver Disease, 2015, 47, e229.	0.4	0
265	Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. Expert Review of Gastroenterology and Hepatology, 2015, 9, 629-650.	1.4	72
266	Hemostatic and Fibrinolytic Abnormalities in Polycystic Ovary Syndrome. Seminars in Thrombosis and Hemostasis, 2014, 40, 600-618.	1.5	18
267	Inter-atrial shunt inversion by the sitting position in a patient with a patent foramen ovale and acute pulmonary embolism. European Heart Journal, 2014, 35, 1032-1032.	1.0	0
268	Hyperuricemia in patients with chronic plaqueÂpsoriasis. Journal of the American Academy of Dermatology, 2014, 70, 127-130.	0.6	45
269	Association of nonalcoholic fatty liver disease with QTc interval in patients with type 2 diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2014, 24, 663-669.	1.1	77
270	Risk of Ischemic Stroke and Decreased Serum Bilirubin Levels. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 702-704.	1.1	13

#	Article	IF	Citations
271	Usefulness of Subclinical Left Ventricular Midwall Dysfunction to Predict Cardiovascular Mortality in Patients With Type 2 Diabetes Mellitus. American Journal of Cardiology, 2014, 113, 1409-1414.	0.7	26
272	Nonalcoholic Fatty Liver Disease Is Independently Associated With an Increased Incidence of Chronic Kidney Disease in Patients With Type 1 Diabetes. Diabetes Care, 2014, 37, 1729-1736.	4.3	129
273	Mortality From Chronic Liver Diseases in Diabetes. American Journal of Gastroenterology, 2014, 109, 1020-1025.	0.2	121
274	Adiponectin and migraine: systematic review of clinical evidence. Neurological Sciences, 2014, 35, 1167-1171.	0.9	11
275	Lower 25-hydroxyvitamin D3 levels and increased risk of liver diseases: is there a causal link?. Endocrine, 2014, 47, 3-4.	1.1	10
276	CKD and Nonalcoholic Fatty Liver Disease. American Journal of Kidney Diseases, 2014, 64, 638-652.	2.1	163
277	Ectopic Fat, Insulin Resistance, and Nonalcoholic Fatty Liver Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1155-1161.	1.1	124
278	Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World Journal of Gastroenterology, 2014, 20, 1724.	1.4	207
279	Reply. Hepatology, 2014, 59, 352-352.	3.6	0
280	Nonalcoholic Fatty Liver Disease Is Associated with Aortic Valve Sclerosis in Patients with Type 2 Diabetes Mellitus. PLoS ONE, 2014, 9, e88371.	1.1	49
281	Increased Red Blood Cell Distribution Width (RDW) is Associated with Higher Glycosylated Hemoglobin (HbA1c) in the Elderly. Clinical Laboratory, 2014, 60, 2095-8.	0.2	24
282	Increased Aortic Pulse Wave Velocity as Measured by Echocardiography Is Strongly Associated with Poor Prognosis in Patients with Heart Failure. Journal of the American Society of Echocardiography, 2013, 26, 714-720.	1.2	31
283	Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 randomized trial). Hepatology, 2013, 58, 1287-1295.	3.6	275
284	Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: Liver ultrasound data from the National Health and Nutrition Examination Survey. Metabolism: Clinical and Experimental, 2013, 62, 392-399.	1.5	140
285	Low 25-hydroxyvitamin D level is independently associated with non-alcoholic fatty liver disease. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, 792-798.	1.1	59
286	Relation of Elevated Serum Uric Acid Levels to Incidence of Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus. American Journal of Cardiology, 2013, 112, 499-504.	0.7	58
287	Inappropriate left ventricular mass independently predicts cardiovascular mortality in patients with type 2 diabetes. International Journal of Cardiology, 2013, 168, 4953-4956.	0.8	15
288	Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 330-344.	8.2	1,381

#	Article	IF	Citations
289	Nonalcoholic Fatty Liver Disease: A Novel Cardiometabolic Risk Factor for Type 2 Diabetes and Its Complications. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 483-495.	1.8	259
290	Nonalcoholic Fatty Liver Disease and Reduced Serum Vitamin D₃ Levels. Metabolic Syndrome and Related Disorders, 2013, 11, 217-228.	0.5	29
291	Uric Acid as a Target of Therapy in CKD. American Journal of Kidney Diseases, 2013, 61, 134-146.	2.1	216
292	Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with TypeÂ2 diabetes. Clinical Science, 2013, 125, 301-310.	1.8	107
293	Diagnosis and Management of Nonalcoholic Fatty Liver Disease and Its Hemostatic/Thrombotic and Vascular Complications. Seminars in Thrombosis and Hemostasis, 2013, 39, 214-228.	1.5	56
294	Non-Alcoholic Fatty Liver Disease Is Associated with an Increased Incidence of Atrial Fibrillation in Patients with Type 2 Diabetes. PLoS ONE, 2013, 8, e57183.	1.1	153
295	Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease - Atherosclerosis as a Major Player in the Natural Course of NAFLD. Current Pharmaceutical Design, 2013, 19, 5177-5192.	0.9	100
296	Glycated Haemoglobin Is Inversely Related to Serum Vitamin D Levels in Type 2 Diabetic Patients. PLoS ONE, 2013, 8, e82733.	1.1	47
297	Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease - Atherosclerosis as a Major Player in the Natural Course of NAFLD. Current Pharmaceutical Design, 2013, 19, 5177-5192.	0.9	72
298	Cardiovascular and systemic risk in nonalcoholic fatty liver disease - atherosclerosis as a major player in the natural course of NAFLD. Current Pharmaceutical Design, 2013, 19, 5177-92.	0.9	48
299	Haemoglobin A1c and diagnosis of diabetes. Not ready for the prime time?. Annals of Clinical Biochemistry, 2012, 49, 508-508.	0.8	3
300	Increased Pulse Pressure Independently Predicts Incident Atrial Fibrillation in Patients With Type 2 Diabetes. Diabetes Care, 2012, 35, 2337-2339.	4.3	20
301	Predictors of Estimated GFR Decline in Patients with Type 2 Diabetes and Preserved Kidney Function. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 401-408.	2.2	178
302	Nonalcoholic Fatty Liver Disease Is Associated With Left Ventricular Diastolic Dysfunction in Patients With Type 2 Diabetes. Diabetes Care, 2012, 35, 389-395.	4.3	159
303	Pasireotide in Cushing's Disease. New England Journal of Medicine, 2012, 366, 2134-2135.	13.9	14
304	Vitamin D, Thrombosis, and Hemostasis: More than Skin Deep. Seminars in Thrombosis and Hemostasis, 2012, 38, 114-124.	1.5	64
305	Further insights on the relationship between bilirubin and C-reactive protein. Clinical Chemistry and Laboratory Medicine, 2012, 50, 2229-30.	1.4	5
306	Comparison of Two Creatinine-Based Estimating Equations in Predicting All-Cause and Cardiovascular Mortality in Patients With Type 2 Diabetes. Diabetes Care, 2012, 35, 2347-2353.	4.3	26

#	Article	IF	Citations
307	The effect of combined calcium and cholecalciferol supplementation on bone mineral density in elderly women with moderate chronic kidney disease. Clinical Nephrology, 2012, 77, 358-365.	0.4	10
308	Association between Nonalcoholic Liver Disease and Chronic Kidney Disease: An Ultrasound Analysis from NHANES 1988â€“1994. American Journal of Nephrology, 2012, 36, 466-471.	1.4	69
309	Serum Uric Acid Levels and Incident Chronic Kidney Disease in Patients With Type 2 Diabetes and Preserved Kidney Function. Diabetes Care, 2012, 35, 99-104.	4.3	207
310	Non-alcoholic fatty liver disease is independently associated with left ventricular hypertrophy in hypertensive Type 2 diabetic individuals. Journal of Endocrinological Investigation, 2012, 35, 215-218.	1.8	54
311	ABO blood group, hypercoagulability, and cardiovascular and cancer risk. Critical Reviews in Clinical Laboratory Sciences, 2012, 49, 137-149.	2.7	117
312	Random plasma glucose measurement may improve the diagnostic specificity of highly sensitive troponin in the emergency department. International Journal of Cardiology, 2012, 155, 172-173.	0.8	5
313	Erythrocyte mechanical fragility is increased in patients with type 2 diabetes. European Journal of Internal Medicine, 2012, 23, 150-153.	1.0	54
314	Increased risk of cardiovascular disease and chronic kidney disease in NAFLD. Nature Reviews Gastroenterology and Hepatology, 2012, 9, 372-381.	8.2	113
315	Aortic and Mitral Annular Calcifications Are Predictive of All-Cause and Cardiovascular Mortality in Patients With Type 2 Diabetes. Diabetes Care, 2012, 35, 1781-1786.	4.3	62
316	Diagnostic significance of haematological testing in patients presenting at the Emergency Department. Emergency Care Journal, 2012, 8, 7.	0.2	2
317	Predictable impact of the routine implementation of the CKD-EPI equation for estimating glomerular filtration rate by a simulation study. Rivista Italiana Della Medicina Di Laboratorio, 2012, 8, 107-113.	0.2	0
318	Increased prevalence of chronic kidney disease in patients with Type 1 diabetes and nonâ€alcoholic fatty liver. Diabetic Medicine, 2012, 29, 220-226.	1.2	62
319	Optimal therapy for reduction of lipoprotein(a). Journal of Clinical Pharmacy and Therapeutics, 2012, 37, 1-3.	0.7	23
320	Higher Random Plasma Glucose Level Is Associated With Increased Plasma Cardiac Troponin in Emergency Department Patients With Suspected Acute Coronary Syndrome. American Journal of Cardiology, 2012, 109, 775-776.	0.7	1
321	Increased prevalence of cardiovascular disease in Type 1 diabetic patients with non-alcoholic fatty liver disease. Journal of Endocrinological Investigation, 2012, 35, 535-40.	1.8	22
322	Pancreatic fat accumulation and its relationship with liver fat content and other fat depots in obese individuals. Journal of Endocrinological Investigation, 2012, 35, 748-53.	1.8	21
323	The role of serum uric acid in cardiovascular disease in Type 2 diabetic and non-diabetic subjects: A narrative review. Journal of Endocrinological Investigation, 2011, 34, 881-886.	1.8	26
324	Arterial thrombus formation in cardiovascular disease. Nature Reviews Cardiology, 2011, 8, 502-512.	6.1	229

#	Article	IF	Citations
325	Hyperthyroidism and Venous Thrombosis: A Casual or Causal Association? A Systematic Literature Review. Clinical and Applied Thrombosis/Hemostasis, 2011, 17, 387-392.	0.7	55
326	Screening and therapeutic management of lipoprotein(a) excess: Review of the epidemiological evidence, guidelines and recommendations. Clinica Chimica Acta, 2011, 412, 797-801.	0.5	20
327	Detection of chronic kidney disease in hospitalized patients: Is one estimating glomerular filtration rate equation better than another?. European Journal of Internal Medicine, 2011, 22, 119-120.	1.0	14
328	Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: Is there a link?. Journal of Hepatology, 2011, 54, 1020-1029.	1.8	152
329	A laboratory standpoint on the role of hemoglobin A1c for the diagnosis of diabetes in childhood: more doubts than certainties?. Pediatric Diabetes, 2011, 12, 183-186.	1.2	21
330	Tomatoes, lycopene-containing foods and cancer risk. British Journal of Cancer, 2011, 104, 1234-1235.	2.9	11
331	Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease. Hepatology, 2011, 53, 375-375.	3.6	12
332	Extra-skeletal effects of vitamin D deficiency in chronic kidney disease. Annals of Medicine, 2011, 43, 273-282.	1.5	27
333	Safety of Recombinant Activated Factor VII in Randomized Clinical Trials. New England Journal of Medicine, 2011, 364, 574-576.	13.9	6
334	Venous Thromboembolism in Chronic Liver Disease. Seminars in Thrombosis and Hemostasis, 2011, 37, 066-076.	1.5	8
335	Hemostatic Disorders in Type 1 Diabetes Mellitus. Seminars in Thrombosis and Hemostasis, 2011, 37, 058-065.	1.5	24
336	Impact of Reference Category and Number of Traits in the Cluster on Risk of Coronary Heart Disease in Metabolic Syndrome: Prospective Data from the Bruneck Study. Metabolic Syndrome and Related Disorders, 2011, 9, 313-318.	0.5	2
337	Risk of all-cause and cardiovascular mortality in patients with chronic liver disease. Gut, 2011, 60, 1602-1603.	6.1	13
338	Relationship Between Early Diastolic Dysfunction and Abnormal Microvolt T-Wave Alternans in Patients With Type 2 Diabetes. Circulation: Cardiovascular Imaging, 2011, 4, 408-414.	1.3	12
339	High-Normal HbA1c Is a Strong Predictor of Type 2 Diabetes in the General Population. Diabetes Care, 2011, 34, 1038-1040.	4.3	47
340	High-Sensitivity C-Reactive Protein, Obesity, and Subclinical Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 1251-1252.	1.1	7
341	Relationship of hepatic steatosis and alanine aminotransferase with coronary calcification. Clinical Chemistry and Laboratory Medicine, 2011, 49, 741.	1.4	0
342	Commentary: Liver enzymes and the risk of adverse cardiovascular outcomes--the lower, the better?. International Journal of Epidemiology, 2011, 40, 1539-1541.	0.9	9

#	Article	IF	Citations
343	Risk of cardiovascular disease and chronic kidney disease in diabetic patients with non-alcoholic fatty liver disease: just a coincidence?. Journal of Endocrinological Investigation, 2011, 34, 544-51.	1.8	14
344	The Use of Recombinant Activated FVII in Postpartum Hemorrhage. Clinical Obstetrics and Gynecology, 2010, 53, 219-227.	0.6	131
345	Epidemiological Association between Uric Acid Concentration in Plasma, Lipoprotein(a), and the Traditional Lipid Profile. Clinical Cardiology, 2010, 33, E76-80.	0.7	55
346	Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients. Diabetologia, 2010, 53, 1341-1348.	2.9	141
347	Non-alcoholic Fatty Liver Disease and Cardiovascular Disease Risk. Current Cardiovascular Risk Reports, 2010, 4, 32-39.	0.8	5
348	Effect of Lovastatin on Primary Prevention of Cardiovascular Events in Mild CKD and Kidney Function Loss: A Post Hoc Analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study. American Journal of Kidney Diseases, 2010, 55, 42-49.	2.1	54
349	Relation of Serum Phosphorus Levels to Ankle Brachial Pressure Index (from the Third National) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.7	43
350	Relationship between Kidney Function and Liver Histology in Subjects with Nonalcoholic Steatohepatitis. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 2166-2171.	2.2	197
351	Glycated hemoglobin (HbA1c): old dogmas, a new perspective?. Clinical Chemistry and Laboratory Medicine, 2010, 48, 609-614.	1.4	62
352	Serum Bilirubin Levels and Cardiovascular Disease Risk. Advances in Clinical Chemistry, 2010, 50, 47-63.	1.8	64
353	Moderate Red Wine Consumption and Cardiovascular Disease Risk: Beyond the â€œFrench Paradoxâ€• Seminars in Thrombosis and Hemostasis, 2010, 36, 059-070.	1.5	151
354	Disorders of Coagulation and Hemostasis in Abdominal Obesity: Emerging Role of Fatty Liver. Seminars in Thrombosis and Hemostasis, 2010, 36, 041-048.	1.5	46
355	Disorders of Hemostasis Associated with Chronic Kidney Disease. Seminars in Thrombosis and Hemostasis, 2010, 36, 034-040.	1.5	183
356	Elevated serum Î³-glutamyltransferase activity is associated with increased risk of mortality, incident type 2 diabetes, cardiovascular events, chronic kidney disease and cancer â€“ a narrative review. Clinical Chemistry and Laboratory Medicine, 2010, 48, 147-157.	1.4	95
357	Prevention and treatment of nonalcoholic fatty liver disease. Digestive and Liver Disease, 2010, 42, 331-340.	0.4	18
358	Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease. New England Journal of Medicine, 2010, 363, 1341-1350.	13.9	1,637
359	Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. Journal of Hepatology, 2010, 53, 713-718.	1.8	202
360	Vaccination, squalene and anti-squalene antibodies: Facts or fiction?. European Journal of Internal Medicine, 2010, 21, 70-73.	1.0	52

#	Article	IF	Citations
361	Relationship between serum gamma-glutamyltransferase and chronic kidney disease in the United States adult population. Findings from the National Health and Nutrition Examination Survey 2001â€“2006. Nutrition, Metabolism and Cardiovascular Diseases, 2010, 20, 583-590.	1.1	51
362	Glomerular filtration rate, albuminuria and risk of cardiovascular and all-cause mortality in type 2 diabetic individuals. Nutrition, Metabolism and Cardiovascular Diseases, 2010, 21, 294-301.	1.1	27
363	Anaemia, independent of chronic kidney disease, predicts all-cause and cardiovascular mortality in type 2 diabetic patients. Atherosclerosis, 2010, 210, 575-580.	0.4	32
364	Usefulness of the triglyceride to high-density lipoprotein cholesterol ratio for predicting mortality risk in type 2 diabetes: Role of kidney dysfunction. Atherosclerosis, 2010, 212, 287-291.	0.4	19
365	Hemostatic abnormalities in endocrine and metabolic disorders. European Journal of Endocrinology, 2010, 162, 439-451.	1.9	56
366	Determinants of anaemia in the very elderly: a major contribution from impaired renal function?. Blood Transfusion, 2010, 8, 44-8.	0.3	16
367	Risks and benefits of replacing conventional plasma lipids with apolipoprotein measurement. Acta Cardiologica, 2009, 64, 413-414.	0.3	0
368	Elevated Serum Uric Acid Concentrations Independently Predict Cardiovascular Mortality in Type 2 Diabetic Patients. Diabetes Care, 2009, 32, 1716-1720.	4.3	111
369	Prevalence of thyroid autoimmunity and subclinical hypothyroidism in persons with chronic kidney disease not requiring chronic dialysis. Clinical Chemistry and Laboratory Medicine, 2009, 47, 1367-71.	1.4	39
370	Clinical usefulness of measuring red blood cell distribution width on admission in patients with acute coronary syndromes. Clinical Chemistry and Laboratory Medicine, 2009, 47, 353-7.	1.4	104
371	Relationship of serum bilirubin concentrations to kidney function and albuminuria in the United States adult population. Findings from the National Health and Nutrition Examination Survey 2001â€“2006. Clinical Chemistry and Laboratory Medicine, 2009, 47, 1055-62.	1.4	43
372	Vitamin B12, Folate, and Anemia in Old Age. Archives of Internal Medicine, 2009, 169, 716.	4.3	4
373	Genetic and biochemical heterogeneity of cardiac troponins: clinical and laboratory implications. Clinical Chemistry and Laboratory Medicine, 2009, 47, 1183-94.	1.4	37
374	Procalcitonin values after dialysis is closely related to type of dialysis membrane. Scandinavian Journal of Clinical and Laboratory Investigation, 2009, 69, 703-707.	0.6	15
375	Extracorporeal Immunoadsorption for the Treatment of Coagulation Inhibitors. Seminars in Thrombosis and Hemostasis, 2009, 35, 076-080.	1.5	19
376	Hemostatic and Fibrinolytic Abnormalities in Endocrine Diseases: A Narrative Review. Seminars in Thrombosis and Hemostasis, 2009, 35, 605-612.	1.5	11
377	Interpatient Phenotypic Inconsistency in Severe Congenital Hemophilia: A Systematic Review of the Role of Inherited Thrombophilia. Seminars in Thrombosis and Hemostasis, 2009, 35, 307-312.	1.5	40
378	Nonalcoholic Fatty Liver Disease as a Contributor to Hypercoagulation and Thrombophilia in the Metabolic Syndrome. Seminars in Thrombosis and Hemostasis, 2009, 35, 277-287.	1.5	123

#	Article	IF	Citations
379	25-Hydroxyvitamin D Deficiency and Inflammation and Their Association with Hemoglobin Levels in Chronic Kidney Disease. American Journal of Nephrology, 2009, 30, 64-72.	1.4	61
380	Biochemical correlates of lipoprotein(a) in a general adult population. Possible implications for cardiovascular risk assessment. Journal of Thrombosis and Thrombolysis, 2009, 27, 44-47.	1.0	7
381	Inherited and acquired risk factors for arterial ischemic stroke in childhood. Journal of Thrombosis and Thrombolysis, 2009, 27, 239-248.	1.0	8
382	Eosinophilia and first-line coagulation testing. Journal of Thrombosis and Thrombolysis, 2009, 28, 90-93.	1.0	9
383	Antithrombotic prophylaxis in patients with von Willebrand disease undergoing major surgery: when is it necessary?. Journal of Thrombosis and Thrombolysis, 2009, 28, 215-219.	1.0	18
384	Hyperthyroidism is associated with shortened APTT and increased fibrinogen values in a general population of unselected outpatients. Journal of Thrombosis and Thrombolysis, 2009, 28, 362-365.	1.0	30
385	Dark chocolate: consumption for pleasure or therapy?. Journal of Thrombosis and Thrombolysis, 2009, 28, 482-488.	1.0	20
386	The red blood cell distribution width is associated with serum levels of thyroid stimulating hormone in the general population. International Journal of Laboratory Hematology, 2009, 31, 581-582.	0.7	18
387	Relationship of Serum Î³â€Glutamyltransferase to Atherogenic Dyslipidemia and Glycemic Control in Type 2 Diabetes. Obesity, 2009, 17, 370-374.	1.5	18
388	Response to â€œNASH Predicts Plasma Inflammatory Biomarkers Independently of Visceral Fat in Menâ€•. Obesity, 2009, 17, 627-627.	1.5	0
389	Bilirubin concentration and cardiovascular risk profile. Liver International, 2009, 29, 315-316.	1.9	9
390	Epidemiological association between fasting plasma glucose and shortened APTT. Clinical Biochemistry, 2009, 42, 118-120.	0.8	41
391	Abnormal serum alanine aminotransferase levels are associated with impaired insulin sensitivity in young women with polycystic ovary syndrome. Journal of Endocrinological Investigation, 2009, 32, 695-700.	1.8	32
392	Hemophilia and cancer: A new challenge for hemophilia centers. Cancer Treatment Reviews, 2009, 35, 374-377.	3.4	43
393	Relationship between serum phosphate and cardiovascular risk factors in a large cohort of adult outpatients. Diabetes Research and Clinical Practice, 2009, 84, e3-e5.	1.1	16
394	Relationship between albuminuria and hemoglobin level. Diabetes Research and Clinical Practice, 2009, 86, e62-e63.	1.1	1
395	Is fasting glucose variability a risk factor for retinopathy in people with type 2 diabetes?. Nutrition, Metabolism and Cardiovascular Diseases, 2009, 19, 334-339.	1.1	38
396	Higher HDL cholesterol levels are associated with a lower incidence of chronic kidney disease in patients with type 2 diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2009, 19, 580-586.	1.1	49

#	Article	IF	Citations
397	Migraine, Valproic Acid, and Lipoprotein(a). Pediatric Neurology, 2009, 41, 78.	1.0	0
398	Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. Journal of Hepatology, 2009, 51, 758-764.	1.8	217
399	Relationship between serum bilirubin and kidney function in non-diabetic and diabetic individuals. Kidney International, 2009, 75, 863.	2.6	21
400	25-Hydroxyvitamin D deficiency is independently associated with cardiovascular disease in the Third National Health and Nutrition Examination Survey. Atherosclerosis, 2009, 205, 255-260.	0.4	371
401	Effect of simvastatin on kidney function loss in patients with coronary heart disease. Atherosclerosis, 2009, 205, 202-206.	0.4	41
402	Anaphylaxis in patients with congenital bleeding disorders and inhibitors. Blood Coagulation and Fibrinolysis, 2009, 20, 225-229.	0.5	27
403	Relationship between thyroid status and renal function in a general population of unselected outpatients. Clinical Biochemistry, 2008, 41, 625-627.	0.8	31
404	Acquired factor VIII inhibitors in oncohematology: A systematic review. Critical Reviews in Oncology/Hematology, 2008, 66, 194-199.	2.0	51
405	Iron and thrombosis. Annals of Hematology, 2008, 87, 167-173.	0.8	112
406	Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia, 2008, 51, 444-450.	2.9	318
407	Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?. Diabetologia, 2008, 51, 1947-1953.	2.9	374
408	Uric acid concentration in patient with acute coronary syndrome. Internal and Emergency Medicine, 2008, 3, 409-411.	1.0	3
409	The effect of iron depletion on chronic hepatitis C virus infection. Hepatology International, 2008, 2, 335-340.	1.9	53
410	Insulin effect on serum potassium and autoâ€inhibition of insulin secretion is intact in a patient with leprechaunism despite severe impairment of substrates metabolism. Diabetes/Metabolism Research and Reviews, 2008, 24, 205-210.	1.7	1
411	Variability of body weight, pulse pressure and glycaemia strongly predict total mortality in elderly type 2 diabetic patients. The Verona Diabetes Study. Diabetes/Metabolism Research and Reviews, 2008, 24, 624-628.	1.7	61
412	Effect of hemodialysis on traditional and innovative cardiac markers. Journal of Clinical Laboratory Analysis, 2008, 22, 59-65.	0.9	20
413	Relationship between serum vitamin D and inflammatory markers in the general population: Comment on the article by Patel et al. Arthritis and Rheumatism, 2008, 58, 913-914.	6.7	3
414	RESPONSE: LETTER TO THE EDITOR. PACE - Pacing and Clinical Electrophysiology, 2008, 31, 261-261.	0.5	0

#	Article	IF	Citations
415	NASH Predicts Plasma Inflammatory Biomarkers Independently of Visceral Fat in Men. Obesity, 2008, 16, 1394-1399.	1.5	180
416	Diabetic retinopathy is associated with an increased incidence of cardiovascular events in TypeÂ2 diabetic patients. Diabetic Medicine, 2008, 25, 45-50.	1.2	76
417	Relationship between soluble CD40 ligand and gamma-glutamyltransferase concentrations in non-drinking, young type 1 diabetic individuals.. Diabetic Medicine, 2008, 25, 1283-8.	1.2	2
418	Association between serum TSH, free T4 and serum liver enzyme activities in a large cohort of unselected outpatients. Clinical Endocrinology, 2008, 68, 481-484.	1.2	60
419	Immune tolerance with rituximab in congenital haemophilia with inhibitors: a systematic literature review based on individual patientsâ€™ analysis. Haemophilia, 2008, 14, 903-912.	1.0	71
420	Help me, Doctor! My D-dimer is raised. Annals of Medicine, 2008, 40, 594-605.	1.5	81
421	Arm Blood Pressure Index and Lipoprotein(a) in Renal Transplant Recipients. Transplantation Proceedings, 2008, 40, 3499.	0.3	0
422	The metabolic syndrome and the risk of arterial and venous thrombosis. Thrombosis Research, 2008, 122, 727-735.	0.8	54
423	Inherited platelet disorders. Clinica Chimica Acta, 2008, 387, 1-8.	0.5	18
424	The paradoxical relationship between serum uric acid and cardiovascular disease. Clinica Chimica Acta, 2008, 392, 1-7.	0.5	191
425	Laboratory, clinical and therapeutic aspects of acquired hemophilia A. Clinica Chimica Acta, 2008, 395, 14-18.	0.5	59
426	Relationship between red blood cell distribution width and kidney function tests in a large cohort of unselected outpatients. Scandinavian Journal of Clinical and Laboratory Investigation, 2008, 68, 745-748.	0.6	139
427	Sudden cardiac death: Prevalence, pathogenesis, and prevention. Annals of Medicine, 2008, 40, 360-375.	1.5	31
428	Plasma D-dimer in the diagnosis of acute aortic dissection. European Heart Journal, 2008, 29, 1207-1207.	1.0	5
429	Association of inflammation with anaemia in patients with chronic kidney disease not requiring chronic dialysis. Nephrology Dialysis Transplantation, 2008, 23, 2879-2883.	0.4	32
430	Detecting of chronic kidney disease in older people by the MDRD and MCQ formulas. Age and Ageing, 2008, 37, 722-722.	0.7	4
431	Prevalence of Subclinical Hypothyroidism in Patients with Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 1296-1300.	2.2	200
432	Increased Risk of CKD among Type 2 Diabetics with Nonalcoholic Fatty Liver Disease. Journal of the American Society of Nephrology: JASN, 2008, 19, 1564-1570.	3.0	187

#	Article	IF	Citations
433	Prevalence of Folic Acid and Vitamin B12 Deficiencies in Patients With Thyroid Disorders. American Journal of the Medical Sciences, 2008, 336, 50-52.	0.4	19
434	Plasma .GAMMA.-glutamyl Transferase Activity Predicts Homocysteine Concentration in a Large Cohort of Unselected Outpatients. Internal Medicine, 2008, 47, 705-707.	0.3	7
435	Is liver fat detrimental to vessels?: intersections in the pathogenesis of NAFLD and atherosclerosis. Clinical Science, 2008, 115, 1-12.	1.8	60
436	Glucose Challenge Test Does not Predict Gestational Diabetes Mellitus. Internal Medicine, 2008, 47, 1171-1174.	0.3	6
437	Natriuretic Peptides for Assessing the Prognosis of Acute Pulmonary Embolism. Chest, 2008, 133, 1531.	0.4	1
438	The use of recombinant factor VIIa in liver diseases. Blood Coagulation and Fibrinolysis, 2008, 19, 341-348.	0.5	21
439	Alanine Aminotransferase as an Independent Predictor of Incident Nonalcoholic Fatty Liver Disease. Clinical Chemistry, 2007, 53, 1159-1159.	1.5	3
440	The Role of Iron in Diabetes and Its Complications: Reponse to Swaminathan et al.. Diabetes Care, 2007, 30, e132-e132.	4.3	5
441	Nonalcoholic Fatty Liver Disease Is Independently Associated With an Increased Incidence of Cardiovascular Events in Type 2 Diabetic Patients. Diabetes Care, 2007, 30, 2119-2121.	4.3	477
442	Prevalence of Nonalcoholic Fatty Liver Disease and Its Association With Cardiovascular Disease Among Type 2 Diabetic Patients: Response to Schindhelm, Heine, and Diamant. Diabetes Care, 2007, 30, e95-e95.	4.3	2
443	Retinopathy Predicts Cardiovascular Mortality in Type 2 Diabetic Men and Women: Response to Juutilainen et al.. Diabetes Care, 2007, 30, e51-e51.	4.3	4
444	Association between 25-hydroxyvitamin D deficiency and cardiovascular disease in type 2 diabetic patients with mild kidney dysfunction. Nephrology Dialysis Transplantation, 2007, 23, 269-274.	0.4	40
445	Effect of Serum Gamma-Glutamyltransferase and Obesity on the Risk of Dyslipidemia and Poor Glycemic Control in Type 2 Diabetic Patients: Cross-Sectional Findings from the Verona Diabetes Study. Clinical Chemistry, 2007, 53, 1867-1869.	1.5	6
446	Vitamin D deficiency among Italian children. Cmaj, 2007, 177, 1529-1530.	0.9	26
447	Reduced von Willebrand Factor-Cleaving Protease Levels in Secondary Thrombotic Microangiopathies and Other Diseases. Seminars in Thrombosis and Hemostasis, 2007, 33, 787-797.	1.5	45
448	Pioglitazone in Nonalcoholic Steatohepatitis. New England Journal of Medicine, 2007, 356, 1067-1069.	13.9	21
449	Relationship between Î³-Glutamyltransferase, Fasting Plasma Glucose, and Triglycerides in the General Population. Clinical Chemistry, 2007, 53, 1866-1867.	1.5	10
450	Plasma PAI-1 Levels Are Increased in Patients With Nonalcoholic Steatohepatitis. Diabetes Care, 2007, 30, e31-e32.	4.3	60

#	Article	IF	Citations
451	Has homocysteine shrunk?. Clinical Chemistry and Laboratory Medicine, 2007, 45, 1419-20.	1.4	2
452	Monitoring glycaemic control: is there evidence for appropriate use of routine measurement of glycated haemoglobin?. Clinical Chemistry and Laboratory Medicine, 2007, 45, 1065-7.	1.4	17
453	Lipoprotein(a), Thrombophilia and Venous Thrombosis. Acta Haematologica, 2007, 117, 246-247.	0.7	6
454	Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutrition, Metabolism and Cardiovascular Diseases, 2007, 17, 517-524.	1.1	355
455	The significance of evaluating conventional inflammatory markers in Von Willebrand factor measurement. Clinica Chimica Acta, 2007, 381, 167-170.	0.5	17
456	Relationship between Î³-glutamyltransferase, lipids and lipoprotein(a) in the general population. Clinica Chimica Acta, 2007, 384, 163-166.	0.5	26
457	Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C. Journal of Hepatology, 2007, 46, 1126-1132.	1.8	150
458	Non-alcoholic fatty liver disease as a determinant of cardiovascular disease. Atherosclerosis, 2007, 190, 18-19.	0.4	15
459	Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis, 2007, 191, 235-240.	0.4	500
460	Ginkgo biloba, inflammation and lipoprotein(a). Atherosclerosis, 2007, 195, 417-418.	0.4	16
461	Prevalence of Nonalcoholic Fatty Liver Disease and Its Association With Cardiovascular Disease Among Type 2 Diabetic Patients. Diabetes Care, 2007, 30, 1212-1218.	4.3	864
462	Relationship between Mean Platelet Volume and Biochemical Components of the Metabolic Syndrome. Clinical Drug Investigation, 2007, 27, 731-732.	1.1	6
463	â€œBuffaloâ€•hump in nonalcoholic fatty liver disease. Hepatology, 2007, 46, 1311-1312.	3.6	1
464	Relationship between ABO blood group and von Willebrand factor levels: from biology to clinical implications. Thrombosis Journal, 2007, 5, 14.	0.9	153
465	Relationship Between Abnormal Microvolt Tâ€Wave Alternans and Poor Glycemic Control in Type 2 Diabetic Patients. PACE - Pacing and Clinical Electrophysiology, 2007, 30, 1267-1272.	0.5	21
466	Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens. Diabetic Medicine, 2007, 24, 1-6.	1.2	207
467	Effect of moderate aerobic exercise on sympatho-vagal balance in Type 2 diabetic patients. Diabetic Medicine, 2007, 24, 370-376.	1.2	50
468	Relationship between lipoprotein(a) and fasting plasma glucose in the general population. European Journal of Clinical Investigation, 2007, 37, 826-827.	1.7	2

#	Article	IF	Citations
469	Relationship between Lipoprotein(a) and Thyroid Function Status in the General Population. Archives of Medical Research, 2007, 38, 905-906.	1.5	5
470	Prophylaxis in von Willebrand disease. Annals of Hematology, 2007, 86, 699-704.	0.8	13
471	Pathogenesis, clinical and laboratory aspects of thrombosis in cancer. Journal of Thrombosis and Thrombolysis, 2007, 24, 29-38.	1.0	56
472	Platelets and lipoprotein(a) in retinal vein occlusion: Mutual targets for aspirin therapy. Thrombosis and Haemostasis, 2007, 97, 1059-1060.	1.8	5
473	Non-alcoholic fatty liver disease is associated with carotid artery wall thickness in diet-controlled Type 2 diabetic patients. Journal of Endocrinological Investigation, 2006, 29, 55-60.	1.8	91
474	Visceral adipose tissue may mediate the link between non-alcoholic fatty liver disease and endocrine abnormalities. Journal of Hepatology, 2006, 45, 454.	1.8	3
475	Relationship between high-sensitivity C-reactive protein levels and liver histology in subjects with non-alcoholic fatty liver disease. Journal of Hepatology, 2006, 45, 879-881.	1.8	79
476	Effects of moderate-intensity exercise training on plasma biomarkers of inflammation and endothelial dysfunction in older patients with type 2 diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2006, 16, 543-549.	1.1	130
477	Inflammatory variables may mediate the link between low plasma vitamin B6 concentrations and cardiovascular disease in type 2 diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2006, 16, e9-e10.	1.1	1
478	Carotid Atherosclerosis and Rheumatoid Arthritis. Annals of Internal Medicine, 2006, 145, 231.	2.0	0
479	Measurement of microvolt T-wave alternans, a new arrhythmic risk stratification test, in Type 2 diabetic patients without clinical cardiovascular disease. Diabetic Medicine, 2006, 23, 207-210.	1.2	12
480	Increased prevalence of cardiovascular disease in Type 2 diabetic patients with non-alcoholic fatty liver disease. Diabetic Medicine, 2006, 23, 403-409.	1.2	150
481	The International Diabetes Federation definition of the metabolic syndrome independently predicts future cardiovascular events in Type 2 diabetic patients. The Valpolicella Heart Diabetes Study. Diabetic Medicine, 2006, 23, 1270-1271.	1.2	14
482	Associations between liver histology and cortisol secretion in subjects with nonalcoholic fatty liver disease. Clinical Endocrinology, 2006, 64, 337-341.	1.2	83
483	Hypovitaminosis D among unselected medical inpatients and outpatients in Northern Italy. Clinical Endocrinology, 2006, 64, 060222010233003.	1.2	5
484	Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease. Clinical Endocrinology, 2006, 64, 679-683.	1.2	156
485	Serum 25-hydroxyvitamin D3 concentrations and carotid artery intima-media thickness among type 2 diabetic patients. Clinical Endocrinology, 2006, 65, 593-597.	1.2	226
486	Serum 25-Hydroxyvitamin D3 Concentrations and Prevalence of Cardiovascular Disease Among Type 2 Diabetic Patients. Diabetes Care, 2006, 29, 722-724.	4.3	244

#	Article	IF	Citations
487	Relations Between Carotid Artery Wall Thickness and Liver Histology in Subjects With Nonalcoholic Fatty Liver Disease. Diabetes Care, 2006, 29, 1325-1330.	4.3	362
488	Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in Type 1 diabetic patients without clinically manifest macroangiopathy. Diabetic Medicine, 2005, 22, 999-1004.	1.2	105
489	Relationship of non-alcoholic hepatic steatosis to cortisol secretion in diet-controlled Type 2 diabetic patients. Diabetic Medicine, 2005, 22, 1146-1150.	1.2	23
490	Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue. Diabetic Medicine, 2005, 22, 1354-1358.	1.2	155
491	Associations between liver histology and early carotid atherosclerosis in subjects with nonalcoholic fatty liver disease. Hepatology, 2005, 42, 974-975.	3.6	26
492	Nonalcoholic Fatty Liver Disease and Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, e117; author reply e117-8.	1.1	2
493	Letter to the Editor. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 2687-2688.	1.1	29
494	Nonalcoholic Fatty Liver Disease and Risk of Future Cardiovascular Events Among Type 2 Diabetic Patients. Diabetes, 2005, 54, 3541-3546.	0.3	517
495	Relation of Nonalcoholic Hepatic Steatosis to Early Carotid Atherosclerosis in Healthy Men: Role of visceral fat accumulation. Diabetes Care, 2004, 27, 2498-2500.	4.3	173
496	Hypoadiponectinemia Is Closely Associated With Nonalcoholic Hepatic Steatosis in Obese Subjects. Diabetes Care, 2004, 27, 2085-2086.	4.3	31
497	Soluble CD40L in Young Type 1 Diabetic Individuals Without Clinical Microvascular and Macrovascular Complications. Diabetes Care, 2004, 27, 1236-1237.	4.3	9
498	Decreased plasma adiponectin concentrations are closely associated with nonalcoholic hepatic steatosis in obese individuals. Clinical Endocrinology, 2004, 61, 700-703.	1.2	101
499	Relationship of nonalcoholic hepatic steatosis to overnight low-dose dexamethasone suppression test in obese individuals. Clinical Endocrinology, 2004, 61, 711-715.	1.2	26
500	The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabetic Medicine, 2004, 21, 52-58.	1.2	248
501	Relationship between fasting insulin and cardiovascular risk factors is already present in young men: the Verona Young Men Atherosclerosis Risk Factors Study. European Journal of Clinical Investigation, 2003, 27, 248-254.	1.7	14
502	HOMA-Estimated Insulin Resistance Is an Independent Predictor of Cardiovascular Disease in Type 2 Diabetic Subjects: Prospective data from the Verona Diabetes Complications Study. Diabetes Care, 2002, 25, 1135-1141.	4.3	493
503	Predictors of insulin sensitivity in Type 2 diabetes mellitus. Diabetic Medicine, 2002, 19, 535-542.	1.2	49
504	Plasma Total Homocysteine Levels Are Associated With von Willebrand Factor, Soluble Intercellular Adhesion Molecule-1, and Soluble Tumor Necrosis Factor-Â Receptors in Young Type 1 Diabetic Patients Without Clinical Evidence of Macrovascular Complications. Diabetes Care, 2001, 24, 1496-1497.	4.3	10

#	Article	IF	Citations
505	Elevated Plasma Levels of Soluble Receptors of TNF-Î± and Their Association with Smoking and Microvascular Complications in Young Adults with Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3805-3808.	1.8	39
506	Elevated Levels of Interleukin-6 in Young Adults With Type 1 Diabetes Without Clinical Evidence of Microvascular and Macrovascular Complications. Diabetes Care, 2001, 24, 956-957.	4.3	58
507	Serum Leptin Concentrations in Young Smokers With Type 1 Diabetes. Diabetes Care, 2001, 24, 793-794.	4.3	8
508	Relation Between Soluble Adhesion Molecules and Insulin Sensitivity in Type 2 Diabetic Individuals: Role of adipose tissue. Diabetes Care, 2001, 24, 1961-1966.	4.3	49
509	Intracellular Partition of Plasma Glucose Disposal in Hypertensive and Normotensive Subjects with Type 2 Diabetes Mellitus1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2073-2079.	1.8	10
510	Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care, 2000, 23, 57-63.	4.3	2,176
511	Cigarette smoking and plasma total homocysteine levels in young adults with type 1 diabetes. Diabetes Care, 2000, 23, 524-528.	4.3	38
512	Effects of glucosamine infusion on insulin secretion and insulin action in humans. Diabetes, 2000, 49, 926-935.	0.3	136
513	Effect of Chronic Treatment with Lacidipine or Lisinopril on Intracellular Partitioning of Glucose Metabolism in Type 2 Diabetes Mellitus1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1544-1550.	1.8	13
514	Chronic cigarette smoking is associated with increased plasma circulating intercellular adhesion molecule 1 levels in young type 1 diabetic patients. Diabetes Care, 1999, 22, 1871-1874.	4.3	18
515	Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes, 1998, 47, 1643-1649.	0.3	750
516	Intimal-Medial Thickness of the Carotid Artery in Nondiabetic and NIDDM Patients: Relationship with insulin resistance. Diabetes Care, 1997, 20, 627-631.	4.3	139
517	Cigarette Smoking and Insulin Resistance in Patients with Noninsulin-Dependent Diabetes Mellitus¹. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3619-3624.	1.8	154
518	A comparison between the HOMA model and the euglycemic clamp in the assessment of insulin sensitivity in vivo. Atherosclerosis, 1997, 135, S20.	0.4	0
519	Obesity worsens cardiovascular risk profiles independently of hyperinsulinaemia. Journal of Internal Medicine, 1997, 241, 463-470.	2.7	5
520	Cigarette Smoking and Insulin Resistance in Patients with Noninsulin-Dependent Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3619-3624.	1.8	126
521	Serum uric acid and related factors in 500 hospitalized subjects. Metabolism: Clinical and Experimental, 1996, 45, 1557-1561.	1.5	68
522	Visceral Fat Accumulation and Its Relation to Plasma Hemostatic Factors in Healthy Men. Arteriosclerosis, Thrombosis, and Vascular Biology, 1996, 16, 368-374.	1.1	139

#	Article	IF	Citations
523	The white blood cell count: its relationship to plasma insulin and other cardiovascular risk factors in healthy male individuals. Journal of Internal Medicine, 1996, 239, 435-441.	2.7	72
524	Plasma factor VII and its relation to adipose tissue fatty acids and other atherogenic risk factors in healthy men. European Journal of Clinical Investigation, 1996, 26, 247-253.	1.7	8
525	Increase in Circulating Products of Lipid Peroxidation in Smokers With IDDM. Diabetes Care, 1996, 19, 1233-1236.	4.3	15
526	Liver Steatosis and Its Relation to Plasma Haemostatic Factors in Apparently Healthy Men - Role of the Metabolic Syndrome. Thrombosis and Haemostasis, 1996, 76, 069-073.	1.8	74
527	Ultrasonographic intra-abdominal depth and its relation to haemostatic factors in healthy males. , 1996, 20, 882-5.		1
528	Relationships of blood pressure to fibrinolysis: influence of anthropometry, metabolic profile and behavioural variables. Journal of Hypertension, 1995, 13, 659-666.	0.3	22
529	Fasting serum insulin in relation to components of the metabolic syndrome in European healthy men: The European fat distribution study. Metabolism: Clinical and Experimental, 1995, 44, 35-40.	1.5	43
530	Plasma fibrinogen in relation to serum insulin, smoking habits and adipose tissue fatty acids in healthy men. European Journal of Clinical Investigation, 1994, 24, 126-130.	1.7	27
531	Relationships of plasminogen activator inhibitor-1 to anthropometry, serum insulin, triglycerides and adipose tissue fatty acids in healthy men. Atherosclerosis, 1994, 106, 139-147.	0.4	39
532	Relationship between uric acid, hyperglycemia and hypertriglyceridemia in general population. Biochemia Medica, 0, , 37-41.	1.2	6
533	From nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease: is it time for a change of terminology?. Hepatoma Research, 0, 2020, .	0.6	3
534	Influence of age and gender variations on glomerular filtration rate estimated by the MCQE formula. Biochemia Medica, 0, , 81-86.	1.2	1
535	Serum prolactin in professional soccer players. Biochemia Medica, 0, , 177-181.	1.2	0
536	Higher Levels of Plasma Hyaluronic Acid and N-terminal Propeptide of Type III Procollagen Are Associated With Lower Kidney Function in Children With Non-alcoholic Fatty Liver Disease. Frontiers in Pediatrics, 0, 10, .	0.9	1